One persistent misconception is that because some medications are easy to buy across the border, all of them are — but Adderall’s Schedule II status puts it in a different, far more restricted category. Another misconception treats price as the only variable, overlooking the documented risk of counterfeit or mislabeled stimulant pills in unregulated markets. A third misconception assumes there’s no better option, when a U.S.-licensed doctor can often help with generic alternatives or assistance programs that address the actual underlying cost concern.